{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T13:35:09Z","timestamp":1769607309174,"version":"3.49.0"},"reference-count":32,"publisher":"Europa Digital & Publishing","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["EuroIntervention"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.4244\/eijy15m11_07","type":"journal-article","created":{"date-parts":[[2016,11,20]],"date-time":"2016-11-20T11:18:03Z","timestamp":1479640683000},"page":"1239-1245","source":"Crossref","is-referenced-by-count":100,"title":["Long-term ticagrelor monotherapy versus standard dual antiplatelet therapy followed by aspirin monotherapy in patients undergoing biolimus-eluting stent implantation: rationale and design of the GLOBAL LEADERS trial"],"prefix":"10.4244","volume":"12","author":[{"given":"Pascal","family":"Vranckx","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Valgimigli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Windecker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Steg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Hamm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"J\u00fcni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hector","family":"Garcia-Garcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerrit","family":"van Es","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Serruys","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2774","reference":[{"key":"key-20161120104532-0","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1161\/CIR.0000000000000095","article-title":"2014 ACC\/AHA\/AATS\/PCNA\/SCAI\/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons.","volume":"130","author":"Fihn SD.","year":"2014","journal-title":"Circulation."},{"key":"key-20161120104532-1","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.4244\/EIJY14M09_01","article-title":"2014 ESC\/EACTS guidelines on myocardial revascularization.","volume":"10","author":"Windecker S.","year":"2015","journal-title":"EuroIntervention."},{"key":"key-20161120104532-2","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1161\/CIRCULATIONAHA.111.071589","article-title":"Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.","volume":"125","author":"Valgimigli M.","year":"2012","journal-title":"Circulation."},{"key":"key-20161120104532-3","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1056\/NEJMoa1001266","article-title":"Duration of dual antiplatelet therapy after implantation of drug-eluting stents.","volume":"362","author":"Park SJ.","year":"2010","journal-title":"N Engl J Med."},{"key":"key-20161120104532-4","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1016\/j.ijcard.2013.03.047","article-title":"Benefits and risks of long-term duration of dual antiplatelet therapy after drug-eluting stenting: a meta-analysis of randomized trials.","volume":"168","author":"Valgimigli M.","year":"2013","journal-title":"Int J Cardiol."},{"key":"key-20161120104532-5","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1161\/CIRCULATIONAHA.111.059022","article-title":"Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience\/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.","volume":"125","author":"Gwon HC.","year":"2012","journal-title":"Circulation."},{"key":"key-20161120104532-6","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","article-title":"Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.","volume":"371","author":"Mauri L.","year":"2014","journal-title":"N Engl J Med."},{"key":"key-20161120104532-7","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1016\/j.jacc.2015.01.039","article-title":"Duration of dual antiplatelet therapy after\u00a0drug-eluting stent implantation: a systematic review and meta-analysis of\u00a0randomized controlled trials.","volume":"65","author":"Giustino G.","year":"2015","journal-title":"J Am Coll Cardiol."},{"key":"key-20161120104532-8","doi-asserted-by":"publisher","first-page":"h1618","DOI":"10.1136\/bmj.h1618","article-title":"Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials.","volume":"350","author":"Navarese EP.","year":"2015","journal-title":"BMJ."},{"key":"key-20161120104532-9","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1016\/j.jacc.2005.01.030","article-title":"The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting.","volume":"45","author":"Gurbel PA.","year":"2005","journal-title":"J Am Coll Cardiol."},{"key":"key-20161120104532-10","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S0140-6736(08)61845-0","article-title":"Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study.","volume":"373","author":"Collet JP.","year":"2009","journal-title":"Lancet."},{"key":"key-20161120104532-11","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1056\/NEJMoa0809171","article-title":"Cytochrome P-450 polymorphisms and response to clopidogrel.","volume":"360","author":"Mega JL.","year":"2009","journal-title":"N Engl J Med."},{"key":"key-20161120104532-12","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1016\/j.jacc.2007.12.044","article-title":"Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study.","volume":"51","author":"Bonello L.","year":"2008","journal-title":"J Am Coll Cardiol."},{"key":"key-20161120104532-13","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes.","volume":"357","author":"Wiviott SD.","year":"2007","journal-title":"N Engl J Med."},{"key":"key-20161120104532-14","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes.","volume":"361","author":"Wallentin L.","year":"2009","journal-title":"N Engl J Med."},{"key":"key-20161120104532-15","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/S0140-6736(09)62191-7","article-title":"Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study.","volume":"375","author":"Cannon CP.","year":"2010","journal-title":"Lancet."},{"key":"key-20161120104532-16","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1093\/eurheartj\/ehi754","article-title":"Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin.","volume":"27","author":"Husted S.","year":"2006","journal-title":"Eur Heart J."},{"key":"key-20161120104532-17","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1161\/CIRCULATIONAHA.110.985325","article-title":"Overview of the 2010 Food and Drug Administration. Cardiovascular and Renal Drugs Advisory Committee meeting regarding ticagrelor.","volume":"123","author":"Gaglia MA.","year":"2011","journal-title":"Circulation."},{"key":"key-20161120104532-18","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1161\/CIRCULATIONAHA.111.047498","article-title":"Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.","volume":"124","author":"Mahaffey KW.","year":"2011","journal-title":"Circulation."},{"key":"key-20161120104532-19","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1111\/j.1538-7836.2010.04160.x","article-title":"In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation.","volume":"9","author":"Armstrong PC.","year":"2011","journal-title":"J Thromb Haemost."},{"key":"key-20161120104532-20","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1056\/NEJMoa1002358","article-title":"A prospective natural-history study of coronary atherosclerosis.","volume":"364","author":"Stone GW.","year":"2011","journal-title":"N Engl J Med."},{"key":"key-20161120104532-21","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1016\/S0140-6736(11)60395-4","article-title":"Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial.","volume":"377","author":"Silber S.","year":"2011","journal-title":"Lancet."},{"key":"key-20161120104532-22","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.","volume":"348","author":"CAPRIE Steering Committee.","year":"1996","journal-title":"Lancet."},{"key":"key-20161120104532-23","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long-term use of ticagrelor in patients with prior myocardial infarction.","volume":"372","author":"Bonaca MP.","year":"2015","journal-title":"N Engl J Med."},{"key":"key-20161120104532-24","doi-asserted-by":"publisher","first-page":"50","DOI":"10.4244\/EIJV5I1A9","article-title":"Assessment of the SYNTAX score in the Syntax study.","volume":"5","author":"Serruys PW.","year":"2009","journal-title":"EuroIntervention."},{"key":"key-20161120104532-25","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.1001\/jama.291.22.2727","article-title":"A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry.","volume":"291","author":"Eagle KA.","year":"2004","journal-title":"JAMA."},{"key":"key-20161120104532-26","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jcin.2010.10.011","article-title":"Incidence, prognostic impact, and influence of antithrombotic therapy on access and nonaccess site bleeding in percutaneous coronary intervention.","volume":"4","author":"Verheugt FW.","year":"2011","journal-title":"JACC Cardiovasc Interv."},{"key":"key-20161120104532-27","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(08)61244-1","article-title":"Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial.","volume":"372","author":"Windecker S.","year":"2008","journal-title":"Lancet."},{"key":"key-20161120104532-28","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1161\/01.CIR.43.3.428","article-title":"Significance of the diagnostic Q wave of myocardial 898 infarction.","volume":"43","author":"Horan LG.","year":"1971","journal-title":"Circulation."},{"key":"key-20161120104532-29","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","article-title":"Clinical end points in coronary stent trials: a case for standardized definitions.","volume":"115","author":"Cutlip DE.","year":"2007","journal-title":"Circulation."},{"key":"key-20161120104532-30","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium.","volume":"123","author":"Mehran R.","year":"2011","journal-title":"Circulation."},{"key":"key-20161120104532-31","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.1093\/eurheartj\/ehu161","article-title":"Prospective validation of the Bleeding Academic Research Consortium classification in the all-comer PRODIGY trial.","volume":"35","author":"Vranckx P.","year":"2014","journal-title":"Eur Heart J."}],"container-title":["EuroIntervention"],"original-title":[],"deposited":{"date-parts":[[2016,11,20]],"date-time":"2016-11-20T11:18:14Z","timestamp":1479640694000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.pcronline.com\/eurointervention\/107th_issue\/204"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["20150318-06  26606735"],"URL":"https:\/\/doi.org\/10.4244\/eijy15m11_07","relation":{},"ISSN":["1774-024X"],"issn-type":[{"value":"1774-024X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]}}}